To test the hypothesis that CH alters the response to targeted therapies, the authors treated the tumor-bearing CH mice with a combination of dabrafenib and trametinib (dab/tram), a BRAF/MEK inhibitor combination commonly used for treating BRAFV600E-mutant ATC patients. Here, BRAF is linked to cyclic hematopoiesis.